Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies
Authors' conclusion
Our experience suggests that MMF is a valuable therapeutic option for the management of JIIM.
Study context
- Population
- Patients with juvenile idiopathic inflammatory myopathies treated with MMF, enrolled in the Juvenile Dermatomyositis Research Group (JDRG) (UK) or followed at the Giannina Gaslini Institute, Genoa, Italy
- Participants
- 29 patients
- Outcome
- Efficacy and safety of MMF
Methodological detailstwo centres (UK JDRG and Gaslini Institute, Italy)
- Two centres (UK JDRG and Gaslini Institute, Italy)
Main finding
As reported in the abstract
Inactive disease, baseline vs last follow-up
- Patients with inactive disease at baseline
- 10.3%
- Patients with inactive disease at last follow-up
- 68.5%
- Normal Manual Muscle Test-8 scores, from–to
- 50.0% to 83.3%
- Normal Childhood Myositis Activity Score, from–to
- 53.5% to 88.9%
- Normal muscle component of DAS, from–to
- 55.2% to 84.2%
- Normal skin component of DAS, from–to
- 31.0% to 42.1%
- Normal VAS for skin disease activity, from–to
- 25.0% to 47.4%
- Normal VAS for overall disease activity, from–to
- 7.1% to 42.1%
Observational data: associations, not effects.
Further findings
CS dose (significantly reduced)
- CS dose, from–to (mg/kg/day)
- 0.3 to 0.1
Safety
- No relevant side effects reported
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). Published 5 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →